Research programme: neuropsychiatric disorder therapeutics

Drug Profile

Research programme: neuropsychiatric disorder therapeutics

Alternative Names: IC 200131

Latest Information Update: 26 May 2014

Price : $50

At a glance

  • Originator Intra-Cellular Therapies
  • Class Small molecules
  • Mechanism of Action Dopamine receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mood disorders; Neurological disorders; Psychiatric disorders

Most Recent Events

  • 26 May 2014 New profile created from 9162647
  • 01 Apr 2014 Preclinical trials in Psychiatric disorders in USA (PO)
  • 01 Apr 2014 Preclinical trials in Neurological disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top